Cargando…
Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
BACKGROUND: While up to 45% of individuals with intellectual and developmental disabilities (IDD) have a comorbid psychiatric disorder, and antipsychotics are commonly prescribed, gender differences in the safety of antipsychotics have rarely been studied in this population. AIMS: To compare men and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal College of Psychiatrists
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998937/ https://www.ncbi.nlm.nih.gov/pubmed/27703773 http://dx.doi.org/10.1192/bjpo.bp.116.002691 |
_version_ | 1782450039051780096 |
---|---|
author | Vigod, Simone N. Lunsky, Yona Cobigo, Virginie Wilton, Andrew S. Somerton, Sarah Seitz, Dallas P. |
author_facet | Vigod, Simone N. Lunsky, Yona Cobigo, Virginie Wilton, Andrew S. Somerton, Sarah Seitz, Dallas P. |
author_sort | Vigod, Simone N. |
collection | PubMed |
description | BACKGROUND: While up to 45% of individuals with intellectual and developmental disabilities (IDD) have a comorbid psychiatric disorder, and antipsychotics are commonly prescribed, gender differences in the safety of antipsychotics have rarely been studied in this population. AIMS: To compare men and women with IDD on medical outcomes after antipsychotic initiation. METHOD: Our population-based study in Ontario, Canada, compared 1457 women and 1951 men with IDD newly initiating antipsychotic medication on risk for diabetes mellitus, hypertension, venous thromboembolism, myocardial infarction, stroke and death, with up to 4 years of follow-up. RESULTS: Women were older and more medically complex at baseline. Women had higher risks for venous thromboembolism (HR 1.72, 95% CI 1.15–2.59) and death (HR 1.46, 95% CI 1.02–2.10) in crude analyses; but only thromboembolism risk was greater for women after covariate adjustment (aHR 1.58, 95% CI 1.05–2.38). CONCLUSIONS: Gender should be considered in decision-making around antipsychotic medications for individuals with IDD. DECLARATION OF INTEREST: None. COPYRIGHT AND USAGE: © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence. |
format | Online Article Text |
id | pubmed-4998937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | The Royal College of Psychiatrists |
record_format | MEDLINE/PubMed |
spelling | pubmed-49989372016-10-04 Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs Vigod, Simone N. Lunsky, Yona Cobigo, Virginie Wilton, Andrew S. Somerton, Sarah Seitz, Dallas P. BJPsych Open Paper BACKGROUND: While up to 45% of individuals with intellectual and developmental disabilities (IDD) have a comorbid psychiatric disorder, and antipsychotics are commonly prescribed, gender differences in the safety of antipsychotics have rarely been studied in this population. AIMS: To compare men and women with IDD on medical outcomes after antipsychotic initiation. METHOD: Our population-based study in Ontario, Canada, compared 1457 women and 1951 men with IDD newly initiating antipsychotic medication on risk for diabetes mellitus, hypertension, venous thromboembolism, myocardial infarction, stroke and death, with up to 4 years of follow-up. RESULTS: Women were older and more medically complex at baseline. Women had higher risks for venous thromboembolism (HR 1.72, 95% CI 1.15–2.59) and death (HR 1.46, 95% CI 1.02–2.10) in crude analyses; but only thromboembolism risk was greater for women after covariate adjustment (aHR 1.58, 95% CI 1.05–2.38). CONCLUSIONS: Gender should be considered in decision-making around antipsychotic medications for individuals with IDD. DECLARATION OF INTEREST: None. COPYRIGHT AND USAGE: © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence. The Royal College of Psychiatrists 2016-04-20 /pmc/articles/PMC4998937/ /pubmed/27703773 http://dx.doi.org/10.1192/bjpo.bp.116.002691 Text en © 2016 The Royal College of Psychiatrists http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Paper Vigod, Simone N. Lunsky, Yona Cobigo, Virginie Wilton, Andrew S. Somerton, Sarah Seitz, Dallas P. Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs |
title | Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs |
title_full | Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs |
title_fullStr | Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs |
title_full_unstemmed | Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs |
title_short | Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs |
title_sort | morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs |
topic | Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998937/ https://www.ncbi.nlm.nih.gov/pubmed/27703773 http://dx.doi.org/10.1192/bjpo.bp.116.002691 |
work_keys_str_mv | AT vigodsimonen morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs AT lunskyyona morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs AT cobigovirginie morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs AT wiltonandrews morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs AT somertonsarah morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs AT seitzdallasp morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs |